Pipeline Includes 25 Programs in Phase 3 and 9 in Registration
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today provided an update to its development pipeline, available at www.pfizer.com/pipeline. The updated pipeline includes an overview of the company's research and a list of compounds in development with targeted indication, phase of development and, for late-stage programs, mechanism of action.
The company has redesigned the format of the development pipeline, providing interactive capabilities that will allow interested parties to search for assets by development stage, therapeutic area and submission type, among other criteria. Additionally, Pfizer will now update its development pipeline four times each year, concurrently with the filing of its annual Form 10-K and quarterly Forms 10-Qs with the Securities and Exchange Commission (SEC).
DISCLOSURE NOTICE: The information contained in the Company's updated development pipeline is as of February 28, 2011. Pfizer assumes no obligation to update forward-looking information contained in the updated pipeline as the result of new information or future events or developments.
This Company's updated pipeline contains forward-looking information about the Company's products in development and additional indications for in-line products that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications and supplemental drug applications that have been or may be filed for products in development and additional indications for in-line products, as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products and such additional indications; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in its reports on Form 10-Q and 8-K.